99 related articles for article (PubMed ID: 25496288)
1. Quantifying the economic benefits of prevention in a healthcare setting with severe financial constraints: the case of hypertension control.
Athanasakis K; Kyriopoulos II; Boubouchairopoulou N; Stergiou GS; Kyriopoulos J
Clin Exp Hypertens; 2015; 37(5):375-80. PubMed ID: 25496288
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
3. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
5. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Grover SA; Coupal L; Zowall H
Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
[TBL] [Abstract][Full Text] [Related]
6. Financial and health costs of uncontrolled blood pressure in the United Kingdom.
Lloyd A; Schmieder C; Marchant N
Pharmacoeconomics; 2003; 21 Suppl 1():33-41. PubMed ID: 12648033
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
8. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
Gladwell D; Henry T; Cook M; Akehurst R
Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
Lotan Y; Buendia Jiménez I; Lenoir-Wijnkoop I; Daudon M; Molinier L; Tack I; Nuijten MJ
BJU Int; 2012 Dec; 110(11 Pt C):E1060-7. PubMed ID: 22686216
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular disease costs associated with uncontrolled hypertension.
Flack JM; Casciano R; Casciano J; Doyle J; Arikian S; Tang S; Arocho R
Manag Care Interface; 2002 Nov; 15(11):28-36. PubMed ID: 12449899
[TBL] [Abstract][Full Text] [Related]
12. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Milne RJ; Vander Hoorn S; Jackson RT
Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
[TBL] [Abstract][Full Text] [Related]
13. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
15. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States.
Ezzati M; Oza S; Danaei G; Murray CJ
Circulation; 2008 Feb; 117(7):905-14. PubMed ID: 18268146
[TBL] [Abstract][Full Text] [Related]
16. Scaling hypertension treatment in 24 low-income and middle-income countries: economic evaluation of treatment decisions at three blood pressure cut-points.
Hutchinson B; Walter A; Campbell N; Whelton PK; Varghese C; Husain MJ; Nugent R; Kostova D; Honeycutt A
BMJ Open; 2024 Apr; 14(4):e071036. PubMed ID: 38626959
[TBL] [Abstract][Full Text] [Related]
17. Prognostic interactions between cardiovascular risk factors.
Vishram JK
Dan Med J; 2014 Jul; 61(7):B4892. PubMed ID: 25123126
[TBL] [Abstract][Full Text] [Related]
18. WHO/ISH total risk approach for primary prevention of cardiovascular disease shows greater decrease in costs for women but not the elderly in Jamaica.
Abdulkadri AO; Tulloch-Reid MK; Francis DK; Gordon-Strachan GM; Younger-Coleman NO; Rocke KD; McFarlane SR; Cunningham-Myrie CA; Ferguson TS; Wilks RJ; Anderson SG
J Clin Epidemiol; 2015 Sep; 68(9):994-1001. PubMed ID: 25819490
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.
Murray CJ; Lauer JA; Hutubessy RC; Niessen L; Tomijima N; Rodgers A; Lawes CM; Evans DB
Lancet; 2003 Mar; 361(9359):717-25. PubMed ID: 12620735
[TBL] [Abstract][Full Text] [Related]
20. Trends in population blood pressure and determinant factors for population blood pressure.
Andersen UO
Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
